APOBEC3A associates with human papillomavirus genome integration in oropharyngeal cancers

Oncogene

Volumn 36, Issue 12, 2017, Pages 1687-1697

  Kondo, S ^a   Wakae, K ^a   Wakisaka, N ^a   Nakanishi, Y ^a   Ishikawa, K ^a   Komori, T ^a   Moriyama Kita, M ^a   Endo, K ^a   Murono, S ^a   Wang, Z ^a   Kitamura, K ^a   Nishiyama, T ^a   Yamaguchi, K ^c   Shigenobu, S ^b   Muramatsu, M ^a   Yoshizaki, T ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b DALIAN UNIVERSITY   (China)

^c NATIONAL INSTITUTE FOR BASIC BIOLOGY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3A; HYDROLASE; INTERFERON; UNCLASSIFIED DRUG; VIRUS DNA; APOBEC3A PROTEIN, HUMAN; CYTIDINE DEAMINASE; DNA BINDING PROTEIN; E2 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN; PROTEIN;

ADULT; ARTICLE; CANCER CELL LINE; CANCER INCIDENCE; CARCINOGENESIS; CONTROLLED STUDY; DNA DENATURATION; DNA INTEGRATION; EXCISION REPAIR; FEMALE; GENE DISRUPTION; GENE DOSAGE; GENE EXPRESSION; GENE SEQUENCE; GENETIC ASSOCIATION; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MUTATIONAL LOAD; NEXT GENERATION SEQUENCING; NUCLEOTIDE SEQUENCE; OROPHARYNX CANCER; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOMATIC HYPERMUTATION; TUMOR BIOPSY; UPREGULATION; VIRUS GENOME; CLASSIFICATION; COMPLICATION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MUTATION; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRIDAE; PHYSIOLOGY; TUMOR CELL LINE; VIROLOGY;

CELL LINE, TUMOR; CYTIDINE DEAMINASE; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME, VIRAL; HUMANS; MUTATION; ONCOGENE PROTEINS, VIRAL; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROTEINS;

EID: 84989944799     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2016.335     Document Type: Article

References (53)

1. Bodily J, Laimins LA. Persistence of human papillomavirus infection: keys to malignant progression. Trends Microbiol 2011; 19: 33-39.
2. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002; 2: 342-350.
3. Mork J, Lie AK, Glattre E, Hallmans G, Jellum E, Koskela P et al. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med 2001; 344: 1125-1131.
4. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans Human papillomaviruses. In: IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, vol. 90, International Agency for Research on Cancer: Lyon, 2007; 1-636.
5. Chaturvedi AK, Anderson WF, Lortet-Tieulent J, Curado MP, Ferlay J, Franceschi S et al. Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers. J Clin Oncol 2013; 31: 4550-4559.
6. Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol 2011; 29: 4294-4301.
7. Gillison ML, Koch WM, Capone RB, Spafford M, Westra WH, Wu L et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000; 92: 709-720.
8. Pett M, Coleman N. Integration of high-risk human papillomavirus: a key event in cervical carcinogenesis? J Pathol 2007; 212: 356-367.
9. Kim SH, Koo BS, Kang S, Park K, Kim H, Lee KR et al. HPV integration begins in the tonsillar crypt and leads to the alteration of p16, EGFR and c-myc during tumor formation. Int J Cancer 2007; 120: 1418-1425.
10. Harris RS, Liddament MT. Retroviral restriction by APOBEC proteins. Nat Rev Immunol 2004; 4: 868-877.
11. Golia-Gaur R, Strebel K. HIV-1 Vif, APOBEC, and intrinsic immunity. Retrovirology 2008; 5: 51.
12. Muramatsu M, Kinoshita K, Fagarasan S, Yamada S, Shinkai Y, Honjo T. Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 2000; 102: 553-563.
13. Burns MB, Temiz NA, Harris RS. Evidence for APOBEC3B mutagenesis in multiple human cancers. Nat Genet 2013; 45: 977-983.
14. Roberts SA, Lawrence MS, Klimczak LJ, Grimm SA, Fargo D, Stojanov P et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat Genet 2013; 45: 970-976.
15. Taylor BJ, Nik-Zainal S, Wu YL, Stebbings LA, Raine K, Campbell PJ et al. DNA deaminases induce break-associated mutation showers with implication of APOBEC3B and 3A in breast cancer kataegis. eLife 2013; 2: e00534.
16. Nik-Zainal S, Alexandrov LB, Wedge DC, Van Loo P, Greenman CD, Raine K et al. Mutational processes molding the genomes of 21 breast cancers. Cell 2012; 149: 979-993.
17. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV et al. Signatures of mutational processes in human cancer. Nature 2013; 500: 415-421.
18. Burns MB, Lackey L, Carpenter MA, Rathore A, Land AM, Leonard B et al. APOBEC3B is an enzymatic source of mutation in breast cancer. Nature 2013; 494: 366-370.
19. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A et al. Mutational heterogeneity in cancer and the search for new cancerassociated genes. Nature 2013; 499: 214-218.
20. Malim MH. APOBEC proteins and intrinsic resistance to HIV-1 infection. Philos Trans R Soc Lond B Biol Sci 2009; 364: 675-687.
21. Okeoma CM, Lovsin N, Peterlin BM, Ross SR. APOBEC3 inhibits mouse mammary tumour virus replication in vivo. Nature 2007; 445: 927-930.
22. Nguyen DH, Hu J. Reverse transcriptase- and RNA packaging signal-dependent incorporation of APOBEC3G into hepatitis B virus nucleocapsids. J Virol 2008; 82: 6852-6861.
23. Bulliard Y, Narvaiza I, Bertero A, Peddi S, Rohrig UF, Ortiz M et al. Structurefunction analyses point to a polynucleotide-accommodating groove essential for APOBEC3A restriction activities. J Virol 2011; 85: 1765-1776.
24. Gee P, Ando Y, Kitayama H, Yamamoto SP, Kanemura Y, Ebina H et al. APOBEC1-mediated editing and attenuation of herpes simplex virus 1 DNA indicate that neurons have an antiviral role during herpes simplex encephalitis. J Virol 2011; 85: 9726-9736.
25. Suspéne R, Aynaud MM, Koch S, Pasdeloup D, Labetoulle M, Gaertner B et al. Genetic editing of herpes simplex virus 1 and Epstein-Barr herpesvirus genomes by human APOBEC3 cytidine deaminases in culture and in vivo. J Virol 2011; 85: 7594-7602.
26. Vartanian JP, Guetard D, Henry M, Wain-Hobson S. Evidence for editing of human papillomavirus DNA by APOBEC3 in benign and precancerous lesions. Science 2008; 320: 230-233.
27. Wang Z, Wakae K, Kitamura K, Aoyama S, Liu G, Koura M et al. APOBEC3 deaminases induce hypermutation in human papillomavirus type 16 upon interferon-β stimulation. J Virol 2014; 88: 1308-1317.
28. Mussil B, Suspene R, Aynaud MM, Gauvrit A, Vartaninan JP, Wain-Hobson S. Human APOBEC3A isoforms translocate to the nucleus and induce DNA double strand breaks leading to cell stress and death. Plos One 2013; 8: e73641.
29. Landry S, Narvaiza I, Linfesty DC, Weitzman MD. APOBEC3A can activate the DNA damage response and cause cell-cycle arrest. EMBO Rep 2011; 12: 444-450.
30. Suspéne R, Henry M, Guillot S, Wain-Hobson S, Vartanian JP. Recovery of APOBEC3-edited human immunodeficiency virus G-4A hypermutants by differential DNA denaturation PCR. J Gen Virol 2005; 86: 125-129.
31. Suspéne R, Guétard D, Henry M, Sommer P, Wain-Hobson S, Vartanian JP. Extensive editing of both hepatitis B virus DNA strands by APOBEC3 cytidine deaminases in vitro and in vivo. Proc Natl Acad Sci USA 2005; 102: 8321-8326.
32. Harris RS, Bishop KN, Sheehy AM, Craig HM, Petersen-Mahrt SK, Watt IN et al. DNA deamination mediates innate immunity to retroviral infection. Cell 2003; 113: 803-809.
33. Noguchi C, Hiraga N, Mori N, Tsuge M, Imamura M, Takahashi S et al. Dual effect of APOBEC3G on Hepatitis B virus. J Gen Virol 2007; 88: 432-440.
34. Robert SA, Gordenin DA. Hypermutation in human cancer genomes: footprints and mechanisms. Nat Rev Cancer 2014; 14: 786-800.
35. Argyris EG, Acheampong E, Wang F, Huang J, Chen K, Mukhtar M et al. The interferon-induced expression of APOBEC3G in human blood-brain barrier exerts a potent intrinsic immunity to block HIV-1 entry to central nervous system. Virology 2007; 367: 440-451.
36. Stenglein MD, Burns MB, Li M, Lengyel J, Harris RS. APOBEC3 proteins mediate the clearance of foreign DNA from human cells. Nat Struct Mol Biol 2010; 17: 222-229.
37. Bonvin M, Achermann F, Greeve I, Stroka D, Keogh A, Inderbitzin D et al. Interferon- inducible expression of APOBEC3 editing enzymes in human hepatocytes and inhibition of hepatitis B virus replication. Hepatology 2006; 43: 1364-1374.
38. Koning FA, Newman EN, Kim EY, Kunstman KJ, Wolinsky SM, Malim MH. Defining APOBEC3 expression patterns in human tissues and hematopoietic cell subsets. J Virol 2009; 83: 9474-9485.
39. Steenbergen RD, Hermsen MA, Walboomers JM, Joenje H, Arwert F, Meijer CJ et al. Integrated human papillomavirus type 16 and loss of heterozygosity at 11q22 and 18q21 in an oral carcinoma and its derivative cell line. Cancer Res 1995; 55: 5465-5471.
40. Roberts I, Ng G, Foster N, Stanley M, Herdman MT, Pett MR et al. Critical evaluation of HPV16 gene copy number quantification by SYBR green PCR. BMC Biotechnol 2008; 8: 57.
41. Nagao S, Yoshinouchi M, Miyagi Y, Hongo A, Kodama J, Itoh S et al. Rapid and sensitive detection of physical status of human papillomavirus type 16 DNA by quantitative real-time PCR. J Clin Microbiol 2002; 40: 863-867.
42. Wilczynski SP, Lin BT, Xie Y, Paz IB. Detection of human papillomavirus DNA and oncoprotein overexpression are associated with distinct morphological patterns of tonsillar squamous cell carcinoma. Am J Pathol 1998; 152: 145-156.
43. Warren CJ, Xu T, Guo K, Griffin LM, Westrich JA, Lee D et al. APOBEC3A functions as a restriction factor of human papillomavirus. J Virol 2015; 89: 688-702.
44. Hoopes JI, Cortez LM, Mertz TM, Malc EP, Mieczkowski PA, Roberts SA. APOBEC3A and APOBEC3B Preferentially Deaminate the Lagging Strand Template during DNA Replication. Cell Rep 2016; 14: 1273-1282.
45. Henderson S, Chakravarthy A, Su X, Boshoff C, Fenton TR. APOBEC-mediated cytosine deamination links PIK3CA helical domain mutations to human papillomavirus-driven tumor development. Cell Rep 2014; 7: 1833-1841.
46. Krokan HE, S'trom P, Aas PA, Pettersen HS, Kavli B, Slupphaug G. Error-free versus mutagenic processing of genomic uracil-relevance to cancer. DNA Repair (Amst) 2014; 19: 38-47.
47. Ohba K, Ichiyama K, Yajima M, Gemma N, Nikaido M, Wu Q et al. In vivo and in vitro studies suggest a possible involvement of HPV infection in the early stage of breast carcinogenesis via APOBEC3B induction. PLoS One 2014; 9: e977787.
48. Kondo S, Wakisaka N, Muramatsu M, Zen Y, Endo K, Murono S et al. Epstein-Barr virus latent membrane protein 1 induces cancer stem/progenitor-like cells in nasopharyngeal epithelial cell lines. J Virol 2011; 85: 11255-11264.
49. Kitamura K, Wang Z, Chowdhury S, Simadu M, Koura M, Muramatsu M. Uracil DNA glycosylase counteracts APOBEC3G-induced hypermutation of hepatitis B viral genomes: excision repair of covalently closed circular DNA. PLoS Pathog 2013; 9: e1003361.
50. Liang G, Kitamura K, Wang Z, Liu G, Chowdhury S, Fu W et al. RNA editing of hepatitis B virus transcripts by activation-induced cytidine deaminase. Proc Natl Acad Sci USA 2013; 110: 2246-2251.
51. Edge SB, Byrd DR, Carducci MA. Compton CC, Fritz AG, Greene F et al. Cancer Staging Manual 7th ed. American Joint Committee on Cancer (AJCC). Springer: New York, NY, USA, 2009.
52. Nakanishi Y, Kondo S, Wakisaka N, Tsuji A, Endo K, Murono S et al. Role of activation-induced cytidine deaminase in the development of oral squamous cell carcinoma. PLoS One 2013; 8: e62066.
53. Park IS, Chang X, Loyo M, Wu G, Chuang A, Kim MS et al. Characterization of the methylation patterns in human papillomavirus type 16 viral DNA in head and neck cancers. Cancer Prev Res (Phila) 2011; 4: 207-217.